Squarepoint’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Squarepoint’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-30,000	Closed	-$2.2M	–	5594
2024 Q3	$2.2M	Buy	+30,000	New	+$2.25M	﹤0.01%	2004
2024 Q2	–	Sell	-20,000	Closed	-$1.38M	–	4771
2024 Q1	$1.38M	Buy	+20,000	New	+$1.37M	﹤0.01%	2343

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Squarepoint's ITCI Position: Q2 2025 in Review

Squarepoint sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 253,193 shares — an estimated $33.4M sold.

Squarepoint first reported a position in ITCI in Q4 2015 and held it in 25 quarters. The position peaked at $33.4M in Q1 2025. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Squarepoint reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Squarepoint sold 253,193 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $33.4M.
Squarepoint first reported a position in Intra-Cellular Therapies Inc. in Q4 2015 and held it in 25 quarters.
Squarepoint's Intra-Cellular Therapies Inc. position peaked at $33.4M in Q1 2025.
3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Squarepoint's 13F filing for Q2 2025, filed 14 Aug 2025.